First Wave BioPharma Inc. (NASDAQ: FWBI) stock gained by 4.85% in the current market trading. First Wave BioPharma which is headquartered in Boca Raton Florida is a biopharmaceutical business that is focused on the development of non-systemic, tailored treatments for GI illnesses. FW-EPI (adrulipase) is also being developed by First Wave BioPharma for the cure of exocrine pancreatic insufficiency (EPI) in cystic fibrosis and persistent pancreatitis patients.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
What’s up with FWBI stock?
First Wave BioPharma announced the appointment of Brian Feaganto First Wave BioPharma’s scientific advisory board (SAB), effective immediately.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Dr. Feagan will serve on the First Wave BioPharma SAB alongside Anthony Opipari, M.D., Ph.D., Richard Marlink, M.D., and Michael Konstan, M.D. The SAB will collaborate with management to help First Wave BioPharma progress its pipeline of development and clinical-stage initiatives centred on its two gut-restricted GI innovations, niclosamide, and adrulipase.
Dr. Feagan is a gastroenterologist who specializes in IBD, such as ulcerative colitis and Crohn’s disease. His study focuses on the development and execution of controlled studies of inflammatory bowel disease therapy. More than 140 multi-center large-scale randomized clinical studies focusing on innovative IBD therapies have been conducted with him as the primary investigator.
James Sapirstein, CEO of First Wave BioPharma stated that,
They’re thrilled to welcome a clinician and researcher of Dr. Feagan’s stature to their growing list of scientific, medical, and industrial thinking leaders. It will provide expert advice to First Wave BioPharma as they advance their many pipeline programmes. Dr. Feagan’s hiring underscores First Wave BioPharma’s enhanced clinical development potential for its unique niclosamide formulations in inflammatory bowel disease areas (IBDs). Dr. Feagan’s experience with inflammatory bowel illness and his scientific skills, in particular, should benefit them in the months and years ahead.